Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/4/2018
SIETES contiene 92261 citas

 
 
 1 a 20 de 3020 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Joseph A. Panel recommends FDA approval of epilepsy drug derived from marijuana. DIA Daily 2018:1. [Ref.ID 102518]
2. Cita con resumen
Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]
4. Cita con resumen
Feuerstein A. Alkermes stumbles as FDA refuses to review depression drug. STAT Daily Recap 2018:6. [Ref.ID 102496]
5. Cita con resumen
The editors. FDA advisers recommend approval of non-opioid drug for opioid withdrawal. Physician's First Watch 2018:4. [Ref.ID 102485]
6. Cita con resumen
Begley S, Empinado H. STAT Plus: CAR-T is a personalized attack on cancer. Here’s how it works. STAT Daily Recap 2018:6. [Ref.ID 102483]
7. Cita con resumen
Loftus P. Biogen and Abbvie take Multiple sclerosis drug off market. Wall St J 2018:1. [Ref.ID 102466]
8. Cita con resumen
11. Cita con resumen
Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med 2018:2 de enero. [Ref.ID 102440]
13. Cita con resumen
Hamel MB. Speed, safety, and industry funding — From PDUFA I to PDUFA VI. N Engl J Med 2017;377:2278-86. [Ref.ID 102166]
15. Cita con resumen
Anónimo. EMA investigating whether ulipristal acetate can damage the liver. DIA Daily 2017:8. [Ref.ID 102159]
16. Cita con resumen
Anónimo. FDA to evaluate increased risk of heart -related death and death from all causes with the gout medicine febuxostat (Uloric). FDA U.S. Food and Drug Administration 2017:15 de noviembre. [Ref.ID 102144]
17. Cita con resumen
Anónimo. FDA approves first digital pill. DIA Daily 2017:1. [Ref.ID 102142]
18. Cita con resumen
Casassus B. Contraception implant removed from global market. Lancet 2017;390:1576. [Ref.ID 102079]
19. Cita con resumen
Edwards IR. A new Erice report considering the safety of medicines in the 21st Century. Drug Saf 2017;40:845-9. [Ref.ID 102074]
20. Cita con resumen
Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]
Seleccionar todas
 
 1 a 20 de 3020 siguiente >>